MarketWatch Reports on Cabot Market View

MarketWatch commentator Peter Brimelow reports on Cabot Market Letter's stance on the market in his November 10 column, writing, "Cabot Market Letter, which has shown itself to be wedded to neither side of the market, is not yet ready to give up on its recent bullishness … as extreme as [Wednesday's market action] was, today didn’t change the general market picture—the market is still attempting to repair the damage from the August-to-early-October crash, but remains as news-driven and volatile as we can remember."

Excerpt from MarketWatch

Is it 1973 all over again?

Commentary: Scary scenario, but not everyone is buying

By Peter Brimelow, MarketWatch November 10, 2011

NEW YORK (MarketWatch)—Wednesday’s bad break has the bears bugalooing. But one judicious bull is standing firm … Cabot Market Letter, which has shown itself to be wedded to neither side of the market, is not yet ready to give up on its recent bullishness. (See Sept. 29 column).

It wrote last night: “We’re not downplaying today’s action, which did plenty of damage and, if nothing else, is a warning shot. But, as extreme as it was, today didn’t change the general market picture—the market is still attempting to repair the damage from the August-to-early-October crash, but remains as news-driven and volatile as we can remember. There’s been enough evidence to put a few lines in the water, but no money is being made on the long side (unless you’re a day trader), which argues for holding a good chunk of cash. We still have about 50% cash in the Model Portfolio, and today is a good reason why.”

“Overall, we still think that a 50-50 approach (about half in, half out of the market) is prudent. If today ends up being the start of a new leg down, we’ll back off and raise even more cash. But if the market and leaders hang in there and eventually get going on the upside, we’ll extend our line. For now, though, we’ll sit tight and see what comes.”

Link to the entire article on MarketWatch


Stock Picks

Loews Corp.

This undervalued stock has strong future earnings growth expectations.

Biogen

Biogen is the market-share leader in treating multiple sclerosis.

Weibo

One of Paul Godwin’s favorite stocks in his Cabot Emerging Markets Investor portfolio.

Cabot Wealth Advisory

Does Alibaba (BABA) Stock Measure Up to Amazon (AMZN)?

By Paul Goodwin on September 23, 2016

Alibaba (BABA) is the Amazon (AMZN) of China. But does BABA stock measure up to AMZN stock? Let’s break it down!Read More >

As Stock Market Trends Change, Invest in these New Leaders

By Michael Cintolo on September 22, 2016

History tells us that all stock market trends change, and if you don’t recognize the leaders of that change early, you risk missing out on the next big winners.Read More >

AMZN Stock vs. FB Stock: Which Is the Better Value Buy?

By J. Royden Ward on September 20, 2016

For the past five years, AMZN stock and FB stock have been two of the market's great growth stories. But could you make the case that either stock is still undervalued? Let’s break it down.Read More >